FDA OKs 'No-Period' Birth Control Pill
Lybrel Is 1st Oral Contraceptive Designed to Stop Menstruation
WebMD News Archive
May 22, 2007 -- The FDA has approved Lybrel, the first low-dose
contraceptive pill that gives women an option to stop their menstrual cycle for an indefinite period of time.
However, women using Lybrel will most likely have unplanned breakthrough
bleeding or spotting, according to the FDA.
Women should consider Lybrel's no-period convenience vs. the chance of
having breakthrough bleeding or spotting, notes Daniel Shames, MD, deputy
director of the Office of Drug Evaluation III at the FDA's Center for Drug
Evaluation and Research.
"I think each woman and her health care provider will have to look at the
data, which we have explicitly defined in our labeling, and decide if this form
of contraception is appropriate for her," Shames told
reporters at a news conference.
This newest form of birth control, developed by
Wyeth Pharmaceuticals, contains 90 micrograms of levonorgestrel and 20
micrograms of ethinyl estradiol -- a combination similar to that found in
other low-dose oral contraceptives. The difference
here: Lybrel replaces the four- to seven-day placebo pill with continuous daily
dosing for nonstop birth control with no menstrual periods.
"Wyeth developed this contraceptive so that women may have an additional
option to manage their cycles. The studies to support this product are a
reflection of our longtime commitment to innovation in women's health," said
Ginger Constantine, Wyeth's vice president of Women's Health Care and Bone
Repair, in 2005 when the new drug application was made.
The FDA approved Lybrel based on two clinical trials, each lasting for one
year, of more than 2,400 women aged 18-49.
The trials showed Lybrel to be a safe and effective contraceptive when used as
Lybrel's labeling provides information on breakthrough bleeding and
"Many of the women that had bleeding or spotting dropped out" of the
clinical trials, Shames says. "By the end of the study, only half of the women
were in the study."
Of the women who started the clinical trials, "maybe 30% or 35% had no
bleeding or spotting" after 13 cycles (about a year), says Shames.